Assessment of Aliskiren Hemifumarate and Amlodipine Besylate in combined Tablet Dosage form by Three Simple UV Spectrophotometric Methods
Ashim K. Sen, Dhanya B. Sen, Aarti S. Zanwar, Rajesh A. Maheshwari & R. Balaraman · Journal of Pharmaceutical Research International · 2021
Background: For a cardiovascular patient's blood pressure to be effectively controlled, more than one drug is required. When coupled with amlodipine besylate (AMLO), a calcium channel blocker, Aliskiren hemifumarate (ALI) is the 1st nonpeptide, low molecular mass, orally active t...
Open access
Research Article
10.9734/jpri/2021/v33i39A32163